Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma

Journal of Neuro-Oncology

Volumn 122, Issue 1, 2015, Pages 145-150

  Levin, Victor A ^a   Mendelssohn, Nancy D ^a   Chan, James ^a   Stovall, Mady C ^a   Peak, Scott J ^a   Yee, Jennie L ^a   Hui, Rita L ^a   Chen, David M ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Bevacizumab (Avastin) therapy; Drug dose; Glioblastoma recurrence; Retrospective analysis

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; TUMOR GROWTH; TUMOR RECURRENCE; UNITED STATES; VENOUS THROMBOEMBOLISM; WOUND HEALING; BRAIN NEOPLASMS; CANCER STAGING; DISEASE COURSE; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; YOUNG ADULT;

EID: 84924620037     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1693-x     Document Type: Article

References (28)

1. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740
2. ®) as treatment of recurrent Glioblastoma Multiforme. Oncologist 14(11):1131–1138
3. Desjardins A, Reardon DA, Herndon JE II et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14(21):7068–7073
4. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745
5. Gonzalez J, Kumar AJ, Conrad CA, Levin VA (2007) Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67(2):323–326
6. Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495
7. Wong ET, Huberman M, Lu XQ, Mahadevan A (2008) Bevacizumab Reverses Cerebral Radiation Necrosis. J Clin Oncol 26:5649–5650
8. Liu AK, Macy ME, Foreman NK (2009) Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 75(4):1148–1154
9. Torcuator R, Zuniga R, Mohan YS et al (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94(1):63–68
10. Lubelski D, Abdullah K, Weil R, Marko N (2013) Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature. J Neurooncol 115(3):317–322
11. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62(5):779–786
12. Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol. 28(12):e188–e189 (author reply e190-182)
13. Levin VA, Edwards MS, Wright DC et al (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64(2–3):237–244
14. Kaplan EL, Meier P (1958) Nonparametric estimates from incomplete observations. J Am Statist Assoc 53:457–481
15. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50(3):163–170
16. Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203–223
17. Hoffman WF, Levin VA, Wilson CB (1979) Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 50(5):624–628
18. Brandes AA, Tosoni A, Spagnolli F et al (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 10(3):361–367
19. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461
20. Chamberlain MC (2008) Pseudoprogression in glioblastoma. J Clin Oncol 26(26):4359 author reply 4359–4360
21. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638
22. Chaskis C, Neyns B, Michotte A, de Ridder M, Everaert H (2009) Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 72(4):423–428
23. Clarke JL, Chang S (2009) Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 9(3):241–246
24. Taal W, Oosterkamp HM, Walenkamp AM et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953
25. Piccioni DE, Selfridge J, Mody RR et al (2014) Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol 16(6):815–822
26. Raizer JJ, Grimm S, Chamberlain MC et al (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22):5297–5305
27. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S (2011) Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 9(4):403–407
28. Rodriguez MA, DeJesus AY, Cheng L (2014) Use of chemotherapy within the last 14 days of life in patients treated at a comprehensive cancer center. JAMA Intern Med 174(6):989–991